Prophylaxis against hepatitis B virus recurrence after liver transplantation: A registry study

Table 1 Baseline characteristics of the recipients and their donors n (%)

	Group A	Group B	Group C	P value
				A <-> B	A <-> C	B <-> C
Number of patients	4684	491	158	-	-	-
Age, mean ± SD (range) (yr)	48.2 ± 9.3 (19-76)	48.3 ± 9.5 (19-73)	48.4 ± 8 (26-71)	0.892	0.998	0.956
Male sex	4136 (88.3)	436 (88.8)	142 (89.9)	0.744	0.544	0.707
MELD score at LT, mean ± SD (range)	18.0 ± 9.5 (6-84)	17.6 ± 10.1 (6-65)	16.8 ± 9.2 (6-50)	0.205	0.250	0.847
Child-Pugh score at LT, mean ± SD (range)	8.9 ± 2.5 (5-15)	8.7 ± 2.8 (5-15)	8.7 ± 2.7 (5-14)	0.391	0.771	0.999
With HCC	2146 (45.8)	251 (51.1)	76 (48.1)	0.025	0.571	0.509
Pre-LT HBeAg positivity	1169 (25.0)	171 (34.8)	58 (36.7)	< 0.001	0.001	0.667
Pre-LT HBV DNA positivity	2248 (48.0)	168 (34.2)	62 (39.2)	< 0.001	0.030	0.251
HBV DNA ≥ 105 copies/mL at LT	1024 (21.9)	40 (8.1)	17 (10.8)	< 0.001	0.001	0.313
Pre-LT antiviral therapy	2604 (55.6)	272 (55.4)	104 (65.8)	0.934	0.011	0.021
Duration of antiviral therapy before LT, mean ± SD (range) (d)	233.4 ± 604.4 (1-7633)	92.8 ± 299.3 (1-3280)	347.1 ± 899.0 (2-7766)	0.804	< 0.001	< 0.001
Number of donors	4684	491	158	-	-	-
Age, mean ± SD (range) (yr)	28.8 ± 6.2 (18-62)	29.1 ± 6.9 (19-61)	29.3 ± 6.3 (20-51)	0.997	0.700	0.737
Male sex	4495 (96.0)	467 (95.1)	147 (93.0)	0.365	0.069	0.315
Deceased donor	4373 (93.4)	424 (86.4)	129 (81.7)	< 0.001	< 0.001	0.147
Living donor	311 (6.6)	67 (13.7)	29 (18.3)	< 0.001	< 0.001	0.147
BMI, mean ± SD (range)	22.4 ± 2.7 (15.5-52.1)	23.2 ± 2.7 (17.6-30.5)	22.6 ± 2.9 (15.8-28.4)	0.069	0.895	0.646
HBsAb positivity	606 (12.9)	68 (13.8)	27 (17.1)	0.568	0.128	0.316
HBcAb positivity	160 (3.4)	21 (4.3)	2 (1.3)	0.323	0.139	0.075

MELD: Model for end-stage liver disease; LT: Liver transplantation; HCC: Hepatocellular carcinoma; HBeAg: Hepatitis B e antigen; HBV DNA: Hepatitis B virus deoxyribonucleic acid; BMI: Body mass index; HBsAb: Hepatitis B surface antibody; HBcAb: Hepatitis B core antibody.